Abbvie-Allergan complete, but critics continue to raise anti-competitive concerns

The Abbvie-Allergan mega-merger may now be complete, but its critics haven’t had their last say.

In a 7-page letter to the Federal Trade Commission, California Attorney General Xavier Becerra called into question the remedies the federal agency imposed to solve the anti-trust concerns intrinsic in the $63 billion deal.